A new University of Toronto study highlights how protein strains vary in the brains of those affected by progressive neurodegenerative diseases such as Parkinson’s suggesting a growing recognition of the need for patient-specific medicines.
Published in journal Nature Neuroscience, these findings represent important implications for people who are affected by progressive neurodegenerative diseases, and those drug development organizations seeking to help them.
The University of Toronto team reviewed the behavior of different strains of the protein known as alpha-synuclein in the brains of mice. Alpha-synuclein is the principal pathological hallmark of Parkinson’s disease, and the research looked at whether different strains of the protein could lead to the manifestation of different diseases.
The team created two different strains of alpha-synuclein that were structurally in test tubes. They the introduced them into mice introduced them into mice and observed carefully. The different structures of the artificial strains led to different results. They found that two different types of diseases were triggered; for example, the mice took different amou...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).